(A, B) Intra-tracheal infection with the USA 300 strain of MRSA induced a significant increase in pulmonary Il21 mRNA (A) and IL-21 protein (B) 24 hr after infection. (C) PBS or 2 μg of IL-21 was …
(A–C) IL-21-mCherry transgenic reporter mice were either not infected or infected with MRSA for 24 hr. Lung cells were analyzed by flow cytometry for the percentage of Il21-mCherry+ CD4+ T cells (A, …
(A–B) Total cellularity of lung was assessed in BAL fluid (A) and lung (B) 24 hr after IL-21 intratracheal instillation. (C) Percentage of neutrophils was assessed by flow cytometry at 24 hr after …
(A) Bone-marrow neutrophils were purified by negative selection using a neutrophil isolation kit (Miltenyi) and either not stimulated or stimulated in vitro with IL-21 (100 ng/ml) for 24 hr in the …
(A) Quantitation of IL-21R MFI in neutrophils treated with or without IL-21 in the presence or absence of peptidoglycan (PG). (B) Lung neutrophils from HKSA-stimulated mice were purified via a …
(A, B) Purified peripheral blood neutrophils were stimulated with PBS (control) or IL-21 (100 ng/ml) for 4 hr, and IL21R mRNA was measured by real-time PCR and normalized to RPL7 expression (A), and …
(A) Human peripheral blood neutrophils were purified by a neutrophil negative selection kit (StemCell Technologies). Shown is CD56 versus CD66b and CD8 versus CD66b staining. (B) Western blotting of …
(A) WT and Il21r KO mice were infected intratracheally with MRSA (2 × 107) and CFU in the lung were quantitated at 4 and 24 hr post-infection. (B) WT and Il21r KO mice were infected in parallel with …
(A) Venn diagram showing the number of differentially expressed genes (1474) in WT vs Il21r KO lungs, with 664 genes downregulated and 810 genes upregulated in the Il21r KO. (B) Heat map showing a …
(A) WT mice were treated intratracheally with 50 μg of control Fc (from IgG1) or IL-21R-Fc protein for 2 days prior to infection with MRSA and lung CFU were quantitated at 4 and 24 hr post-infection …
MRSA infection, as detailed in the legend to Figure 6A. (A, B) Pathology and neutrophil infiltration scores were assessed from H and E-stained lung sections shown in Figure 6B. (C) RNA-Seq was …
(A) Peripheral blood neutrophils from normal donors (NDs) or AD-HIES patients (PTs) were assayed using an in vitro MRSA killing assay in the absence or presence of IL-21 (100 ng/ml). (B) RT-PCR was …
(A) In wild-type (WT) mice, MRSA produces SEB, which bridges between T cells and dendritic cells by interacting with TCR and MHCII, leading to the production of IL-21 by CD4+ T cells. IL-21 …
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Strain, strain background (S. aureus) | FPR3757 | ATCC | ATCC BAA-1556 | |
Strain, strain background (Streptococcus pyogenes) | NZ131 | ATCC | ATCC-BAA-1633 | |
Genetic reagent (M. musculus) | Il21r-/- | Ozaki et al. Science 298:1630, 2002 | ||
Genetic reagent (M. musculus) | mCherry Il21 | Wang et al. P.N.A.S. 108:9542, 2011 | ||
Genetic reagent (M. musculus) | C57BL/6-Tg(Stat3*)9199Alau/J | Jackson Laboratory | Stock # 027952 | |
Biological sample (S. aureus) | Staph enterotoxin B | List Biological Laboratories | #122 | |
Biological sample (S. aureus) | Heat-killed S. aureus | In Vivo Gen | tlrl-hksa | |
Antibody | Mouse monoclonal anti-granzyme B | Biolegend | GB11 RRID:AB_2562195 | flow cytometry 1:100 |
Antibody | Mouse monoclonal anti-granzyme B | Biolegend | clone M3304B06 RRID:AB_2565266 | WB (1:500) |
Antibody | Mouse monoclonal anti-Ly6G (1A8) | BioX Cell | RRID: AB_1107721 | Blocking Ab |
Antibody | Mouse monoclonal anti-IFNAR (MAR1-5A3) | BioX Cell | RRID: AB_2687723 | Blocking Ab |
Antibody | Mouse monoclonal MOPC-21 | BioX Cell | RRID: AB_1107784 | Blocking Ab |
Antibody | Rat monoclonal 2A3 | BioX Cell | RRID: AB_1107769 | Blocking Ab |
Antibody | Mouse monoclonal anti-human IL21 | BD Biosciences | clone 3A3-N2.1 RRID:AB_2738933 | flow cytometry 1:100 |
Antibody | Rat monoclonal anti-mouse IL-21R | BD Biosciences | clone 4A9 | flow cytometry 1:100 |
Antibody | Mouse monoclonal anti-human IL-21R | Biolegend | clone 2G1-K12 RRID:AB_2123988 | flow cytometry 1:100 |
Antibody | Mouse monoclonal anti-human CD66b | Biolegend | clone G10F5 RRID:AB_2563294 | flow cytometry 1:100 |
Antibody | Mouse monoclonal anti-CD11b | Biolegend | clone M1/70 RRID:AB_312789 | flow cytometry 1:100 |
Peptide, recombinant protein | Recombinant mouse IL-21 | R and D Systems | 594 ML-100/CF | |
Peptide, recombinant protein | Recombinant human IL-21 | R and D Systems | 8879-IL-050/CF | |
Peptide, recombinant protein | Recombinant human GM-CSF | R and D Systems | 215 GM | |
Peptide, recombinant protein | Recombinant human IL-4 | R and D Systems | 204-IL | |
Peptide, recombinant protein | Z-AAD-CMK | Enzo Life Sciences | BML-P165 | |
Commercial assay or kit | IL-21 ELISA | R and D Systems | DY594 | |
Commercial assay or kit | Granzyme B ELISA | Ebioscience | BMS2027 RRID:AB_2575322 | |
Commercial assay or kit | IFNalpha ELISA | Ebioscience | 50-246-672 | |
Commercial assay or kit | Cell Rox Deep Red staining kit | InVitrogen/Molecular Probes | C10491 | |
Commercial assay or kit | Mouse neutrophil isolation kit | Miltenyi | 130-097-658 | |
Commercial assay or kit | Human neutrophil isolation kit | Stem Cell Technologies | 19666 | |
Commercial assay or kit | KAPA stranded mRNA-Seq library kit | Kapa Biosystems | KK8580 | |
Chemical compound, drug | Peptidoglycan from S. aureus | Sigma | #77140 |
RNA-Seq analysis was performed on lung mRNA isolated 7 or 24 hr after treatment of WT mice with PBS or IL-21.
RNA-Seq was performed on highly purified human neutrophils incubated for 4 or 24 hr with PBS or IL-21 in the absence or presence of heat-killed S. aureus.
RNA-Seq analysis from WT and Il21r KO mouse lungs 4 and 24 hr after MRSA infection.
RNA-Seq was performed on total lung mRNA either before MRSA infection or 4 hr after infection of mice that were pre-treated with either control Fc protein or IL-21R-Fc fusion protein.
RNA-Seq analysis of neutrophils from normal human donors and AD-HIES patients; cells were either not treated or treated for 4 hr with IL-21, IFNβ, or IL-21 +IFNβ.